Treatment of Patients With Nocturia

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Serenity Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Male and female 50 years or older

• Nocturia of 6 or more months duration averaging 2 episodes or more per night

Exclusion Criteria:

• CHF

• Diabetes

• Diabetes Insipidus

• Renal Insufficiency

• Hepatic Insufficiency

• Incontinence

• Illness requiring steroids

• Current or past urologic malignancy

• Nephrotic Syndrome

• Unexplained pelvic masses

• Urinary bladder neurological dysfunction

• Urinary bladder surgery or radiotherapy

• Sleep Apnea

• Pregnant or breast feeding